188 related articles for article (PubMed ID: 35353168)
1. Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions.
Arastu AH; Elstrott BK; Martens KL; Cohen JL; Oakes MH; Rub ZT; Aslan JJ; DeLoughery TG; Shatzel J
JAMA Netw Open; 2022 Mar; 5(3):e224488. PubMed ID: 35353168
[TBL] [Abstract][Full Text] [Related]
2. Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014.
Akhuemonkhan E; Parian A; Carson KA; Hutfless S
Inflamm Bowel Dis; 2018 Jul; 24(8):1801-1807. PubMed ID: 29669068
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
4. A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
Cohen J; Khudanyan A; Lu J; Wing J; Olson S; Deloughery T; Shatzel JJ
Am J Hematol; 2020 Dec; 95(12):1572-1577. PubMed ID: 32918335
[TBL] [Abstract][Full Text] [Related]
5. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
6. Safety of Intravenous Iron Following Infusion Reactions.
Stojanovic S; Graudins LV; Aung AK; Grannell L; Hew M; Zubrinich C
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1660-1666. PubMed ID: 33248279
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. IV iron formulations and use in adults.
Van Doren L; Auerbach M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):622-629. PubMed ID: 38066930
[TBL] [Abstract][Full Text] [Related]
9. Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.
Dave CV; Brittenham GM; Carson JL; Setoguchi S
Ann Intern Med; 2022 May; 175(5):656-664. PubMed ID: 35344378
[TBL] [Abstract][Full Text] [Related]
10. The available intravenous iron formulations: History, efficacy, and toxicology.
Auerbach M; Macdougall I
Hemodial Int; 2017 Jun; 21 Suppl 1():S83-S92. PubMed ID: 28371203
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
12. Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.
Wetmore JB; Weinhandl ED; Zhou J; Gilbertson DT
PLoS One; 2017; 12(1):e0171098. PubMed ID: 28135334
[TBL] [Abstract][Full Text] [Related]
13. Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
Trumbo H; Kaluza K; Numan S; Goodnough LT
Drug Saf; 2021 Jan; 44(1):107-119. PubMed ID: 33237523
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of intravenous iron-induced hypophosphatemia.
Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
[TBL] [Abstract][Full Text] [Related]
16. Association of iron infusion reactions with ABO blood type.
Butt A; Muradashvili T; Soliman S; Li F; Burns AJ; Brooks A; Browning S; Bar N; Borgman G; Goshua G; Hwa J; Martin K; Rinder H; Tormey C; Pine AB; Bona RD; Lee AI; Neparidze N
Eur J Haematol; 2022 Nov; 109(5):519-525. PubMed ID: 35871468
[TBL] [Abstract][Full Text] [Related]
17. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
18. Ferumoxytol for the treatment of iron deficiency anemia.
Auerbach M; Chertow GM; Rosner M
Expert Rev Hematol; 2018 Oct; 11(10):829-834. PubMed ID: 30188740
[TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
20. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
Gilmartin CE; Hoang T; Cutts BA; Leung L
Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
